• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15863265).
  

PubMed=9146668; DOI=10.1016/S0022-5347(01)64778-5
Ramp U., Jaquet K., Reinecke P., Schardt C., Friebe-Hoffmann U., Nitsch T., Marx N., Gabbert H.E., Gerharz C.-D.
Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type.
J. Urol. 157:2345-2350(1997)

PubMed=11139287; DOI=10.1038/sj.cdd.4400746
Dejosez M., Ramp U., Mahotka C., Krieg A., Walczak H., Gabbert H.E., Gerharz C.-D.
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Cell Death Differ. 7:1127-1136(2000)

CLPUB00411
Petek O.
Analysis of expression and mutation of the antimetastatic gene NM23 in human renal carcinoma cell lines and epithelioid sarcomas.
Thesis MD (2002); Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany

CLPUB00407
Krieg A.
Characterization and functional analysis of the TRAIL system and the inhibitor of apoptosis protein (IAP) family in human neoplasia.
Thesis MD (2005); Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany

PubMed=15863265; DOI=10.1016/j.canlet.2004.09.045
Reinecke P., Kalinski T., Mahotka C., Schmitz M., Dejosez M., Gabbert H.E., Gerharz C.-D.
Paclitaxel/taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Cancer Lett. 222:165-171(2005)